• Enhanced Tools for COVID-9 Omicron Variant Research
    AMSBIO has announced new tools for COVIC-19 Omicron variant (B.1.1.529) research.

Laboratory Products

Enhanced Tools for COVID-9 Omicron Variant Research

Jan 12 2022

AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognise the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralises its interaction with ACE2. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Research has shown that ACE2 mediates COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein.

AMSBIO’s new Spike neutralising monoclonal antibodies (clone G10xA5 and G10xA1) recognise the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralise its interaction with ACE2. Both these neutralising antibodies have been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit.

Also new is AMSBIO’s Spike S1 RBD: ACE2 Inhibitor Screening Assay Kit. This key colorimetric assay kit is designed for screening and profiling inhibitors or neutralising antibodies of the interaction between the Omicron variant SARS-CoV-2 Spike RBD and human ACE2. The new assay requires only a few steps to use. Firstly, SARS-CoV-2 Spike RBD (B.1.1.529, Omicron variant) is coated on a 96-well plate overnight. After washing and blocking, the protein is pre-incubated with an inhibitor or neutralising antibody. Following incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP then addition of a colorimetric HRP substrate to produce colour, which can be quenched and measured using a UV/Vis microplate reader.

Since the beginning of the global pandemic, several new SARS-CoV-2 variants have emerged, each with differing mutations that impact transmissibility, COVID-19 disease severity, and the effectiveness of vaccines. AMSBIO now offers a series of recombinant antigens and pseudotyped lentivirus with key Spike mutations in order to evaluate the efficacy of antibodies and vaccines. These products form part of a larger COVID-19 Tools for Research portfolio, including other high quality recombinant proteins, Spike pseudotyped lentivirus, and reagents for vaccine development and evaluation.

More information online
 


Digital Edition

Lab Asia December 2021

December 2021

Chromatography - A novel approach to the analysis of alcohols in hydrocarbon streams by gas chromatography - Smart Evaporation Solutions for Academic Labs - Streamlined Solutions for Natural P...

View all digital editions

Events

Nano Tech 2022

Jan 26 2022 Tokyo, Japan

AUTOMATICON

Jan 26 2022 Warsaw, Poland

SLAS 2022

Feb 05 2022 Boston, USA & online

Asia Pharma Expo/Asia Lab Expo

Mar 03 2022 Dhaka, Bangladesh

SIAF Guangzhou

Mar 03 2022 Guanghzou, China

View all events